With central banks signaling tighter policy, bond yields adjusting across regions and energy prices swinging with geopolitical headlines, cash flows matter more than ever. Instead of chasing headlines, this article focuses on companies where the share price trades below an internally assessed fair value based on discounted cash flow, using the SWS DCF framework. That points to stocks where the market price may not fully reflect the underlying cash generation potential. In the sections ahead, you will see 3 of the most compelling stocks from the Undervalued Stocks Based On Cash Flows screener and why they stand out today.

MonotaRO (TSE:3064)

Overview: MonotaRO is an online distributor that supplies factories and workplaces with a wide range of maintenance, repair and operations products, from safety gear and tools to office, laboratory and medical supplies, serving customers in Japan and overseas through its e commerce platform.

Operations: MonotaRO generates all of its ¥350,356 million revenue from indirect material sales to factories in Japan.

Market Cap: ¥897.1b

MonotaRO stock sits on the Undervalued Stocks Based On Cash Flows screener because the share price trades below the SWS DCF estimate of fair value. The business combines double digit earnings growth, high returns on equity around the high 20% range and rising profit margins. Recent results show higher revenue and net income, and the company has been actively buying back shares, which can be supportive for existing shareholders. At the same time, the P/E multiple is well above the trade distributors average and the balance sheet leans heavily on external funding, while cash flows do not fully cover the dividend. For investors, that mix of quality, growth and funding risk makes MonotaRO a stock worth a closer look within this cash flow focused screen.

MonotaRO’s high 20% returns on equity and rising margins suggest a stronger story than the headline P/E ratio implies, so review the 4 key rewards and 1 important warning sign that could reframe how you see the funding and buybacks

Round One (TSE:4680)

Overview: Round One operates indoor leisure complexes that bundle bowling, arcade games, karaoke, billiards and its Spo-Cha multi sport arenas into one destination. This gives customers in Japan and overseas a mix of casual entertainment and family friendly activities under a single roof.

Operations: Round One generates most of its revenue in Japan at ¥108,689 million, with ¥79,662 million from the United States of America and ¥1,196 million from other regions.

Market Cap: ¥271.0b

Round One stock screens as interesting because it combines solid fundamentals with a price that sits well below the SWS DCF estimate of fair value, while the P/E multiple is lower than many peers in the hospitality space. Earnings growth has been strong over the past five years and analysts still see room for further gains. However, the share price has recently lagged the broader industry. That disconnect, together with high returns on equity around 20% and stable margins, is what catches the eye. The main question for investors is how comfortable they are with a funding structure that relies heavily on external borrowing if conditions become tougher.

Round One’s earnings and returns appear out of sync with the share price. This raises a simple question for investors: what is the market missing in the analyst forecasts for Round One and the funding story behind it?

Chugai Pharmaceutical (TSE:4519)

Overview: Chugai Pharmaceutical is a Japan based drug company focused on prescription medicines for cancer, autoimmune conditions and rare diseases, using biologic therapies and targeted treatments developed in house and through its close partnership with Roche.

Operations: Chugai Pharmaceutical generates ¥1,291,229 million in revenue from pharmaceuticals, with reported sales across Japan and Switzerland.

Market Cap: ¥12,590.1b

Chugai Pharmaceutical stands out on a cash flow focused screen because it combines high profitability, with net margins around 35% and strong return on equity in the low 20% range, with analyst expectations for revenue and earnings growth ahead of the broader Japan market. Recent Q1 2026 results show healthy sales and profit. The company is leaning into biologics, personalized medicine and AI driven drug discovery partnerships, such as the Gero deal, which could open up new high value therapies over time. The flip side is heavy dependence on a handful of blockbuster drugs, meaningful reliance on Roche and a P/E multiple that already prices in a lot of optimism, so investors need to decide whether the pipeline and manufacturing investments truly justify that confidence.

Chugai Pharmaceutical’s high margins and focus on biologics, personalized medicine and AI partnerships hint at a story the market may not fully appreciate yet. The analyst forecasts for Chugai Pharmaceutical could be the missing link that explains whether those headline returns truly capture the real opportunity or quietly mask a risk that only shows up in the fine print.

The three stocks highlighted here are only a sample of what this cash flow focused idea uncovers, as the full Undervalued Stocks Based On Cash Flows screener surfaces 54 more companies with equally compelling narratives around discounted cash flows and implied value gaps. Use Simply Wall St to identify, filter and analyze the specific catalysts and cash flow stories that matter to you so you can focus on the opportunities you find most compelling from this broader list.

Take Control of Your Investment Journey

If Round One or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before Others?

Fresh stock ideas can move from quiet accumulation to breakout momentum faster than many expect, and once they are flying, ideal entry points shrink, so consider acting sooner rather than later.

• Spot companies quietly building momentum across bleeding edge tech by scanning the 49 AI infrastructure stocks while it still sits under the radar for now.
• Pinpoint cash rich operators with sturdy balance sheets using the curated list of solid balance sheet and fundamentals (40 results) before the crowd catches the next wave of interest.
• Identify income opportunities from sturdier payouts with the hand picked 47 dividend fortresses while yields remain attractive and before prices start reducing the apparent value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.